Sample size determination in group-sequential clinical trials with two co-primary endpoints-Reference-Cited by-同舟云学术

Sample size determination in group-sequential clinical trials with two co-primary endpoints

Published:2014-03-27 Issue:17 Volume:33 Page:2897-2913
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statist. Med.

Author:

Asakura Koko¹²,Hamasaki Toshimitsu¹²,Sugimoto Tomoyuki³,Hayashi Kenichi¹,Evans Scott R.⁴,Sozu Takashi⁵

Affiliation:

1. Department of Biomedical Statistics; Osaka University Graduate School of Medicine; Osaka Japan

2. Office of Biostatistics and Data Management, Research and Development Initiative Center; National Cerebral and Cardiovascular Center; Osaka Japan

3. Department of Mathematical Sciences; Graduate School of Science and Technology, Hirosaki University; Aomori Japan

4. Department of Biostatistics and the Center for Biostatistics in AIDS Research; Harvard School of Public Health; Boston MA U.S.A.

5. Department of Biostatistics; Kyoto University School of Public Health; Kyoto Japan

Funder

National Institute of Allergy and Infectious Diseases

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Reference33 articles.

1. Committee for Medicinal Products for Human Use (CHMP) Guideline on Medicinal Products for the Treatment Alzheimer's Disease and Other Dementias (CPMP/EWP/553/95 Rev.1) 2008

2. Multiple co-primary endpoints: medical and statistical solutions;Offen;Drug Information Journal,2007

3. Some controversial multiple testing problems in regulatory applications;Hung;Journal of Biopharmaceutical Statistics,2009

4. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial;Xiong;Clinical Trials,2005

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sample size calculation in clinical trials with two co‐primary endpoints including overdispersed count and continuous outcomes;Pharmaceutical Statistics;2023-09-07

2. A gated group sequential design for seamless Phase II/III trial with subpopulation selection;BMC Medical Research Methodology;2023-01-03

3. On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes;Contemporary Clinical Trials;2021-02

4. Approval policies for modifications to machine learning‐based software as a medical device: A study of bio‐creep;Biometrics;2020-10-11

5. Interim Monitoring for Futility in Clinical Trials With Two Co-Primary Endpoints Using Prediction;Statistics in Biopharmaceutical Research;2019-11-04